当前位置:首页 > 报告详情

Esperion-2026-JPM.pdf

上传人: 明**** 编号:1069759 2026-01-17 24页 6.46MB

1、Executing Today While Building for Tomorrow 2025 Esperion Therapeutics,Inc.All rights reserved.J.P.Morgan Healthcare Conference I January 2026Sheldon Koenig,President and CEOForward-looking Statements&DisclosuresThis investor presentation contains forward-looking statements that are made pursuant to

2、 the safe harbor provisions of the federal securities laws,including statements regarding marketing strategy and commercialization and business development plans,current and planned operational expenses,expected profitability,future operations,commercial products,clinical development,plans for poten

3、tial future product candidates,financial condition and outlook,including expected cash runway and profitability,and other statements containing the words“anticipate,”“believe,”“estimate,”“expect,”“intend,”“may,”“plan,”“predict,”“project,”“suggest,”“target,”“potential,”“will,”“would,”“could,”“should,

4、”“continue,”and similar expressions.Any express or implied statements contained in this investor presentation that are not statements of historical fact may be deemed to be forward-looking statements.Forward-looking statements involve risks and uncertainties that could cause Esperions actual results

5、 to differ significantly from those projected,including,without limitation,the net sales,profitability,and growth of Esperions commercial products,clinical activities and results,supply chain,commercial development and launch plans,business development,the outcomes and anticipated benefits of legal

6、proceedings and settlements,and the risks detailed in Esperions filings with the Securities and Exchange Commission.Any forward-looking statements contained in this investor presentation speak only as of the date hereof,and Esperion disclaims any obligation or undertaking to update or revise any for

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1. **财务与增长**:2025年美国净产品销售额1.56亿-1.60亿美元,同比增长35%-38%;现金及现金等价物初步数据未披露,全年总收入(含里程碑)达9100万美元。 2. **商业化进展**:美国零售处方量同比增长34%,处方医生数达4.5万名;90%商业及Medicare覆盖;全球合作伙伴包括日本、加拿大等41国,累计治疗患者超60万。 3. **管线亮点**: - 三重组合疗法(bempedoic acid+ezetimibe+他汀)预计2027年获批,LDL-C降低>60%。 - ACLY抑制剂ESP-2001针对PSC(原发性硬化性胆管炎),2026年启动I期临床,潜在市场超10亿美元。 4. **财务指引**:2026年运营费用2.10亿-2.45亿美元(研发4.00亿-5.00亿,SG&A 1.70亿-1.95亿)。 5. **愿景**:目标2040年拥有至少5款上市产品,通过BD及内部管线拓展实现。
**增长动力何在?** **新药前景如何?** **财务表现怎样?**
客服
商务合作
小程序
服务号
折叠